INTERNATIONAL MYELOMA SOCIETY

19th International Myeloma Society Annual Meeting

 

25-27 August, Los Angeles
Close
N. Poster
Poster title
Applicant name
Status
  P-03 A first-in-human phase 1 study of oral LOXO-338, a ive BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress) NAIMAH BOLAJI Received Received
  P-04 Successful Ex-plantation of Left Ventricular Assist Device After Cardiac Recovery with Daratumumab Therapy in a Patient with End Stage Heart Failure due to Immunoglobulin Light-chain (AL) Amyloidosis Daryl Tan Received Received
  P-06 Real World Experience of Patients Treated With Idecabtagene Vicleucel: A BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma Annie Hayes Received Received
  P-12 Cevostamab is efficacious and well tolerated in patients aged 65 and =65 years with relapsed/refractory multiple myeloma (RRMM) James Bailey Received Received
  P-18 Optimized affinity CD38 CAR-NK cells with CD38 KO show promising in-vivo activity in a Multiple Myeloma model Michael ODwyer Received Received
  P-21 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibody-dependent cell cytotoxicity Sabrin Tahri Received Received
  P-25 Investigating the effect of irreversible proteasome inhibitor Carfilzomib in in vivo models of Cardiometabolic Syndrome and early stage HFrEF. Prophylactic role of Metformin. Evangelos Terpos Received Received
  P-31 Artificial intelligence analysis of whole-body magnetic resonance imaging of patients with multiple myeloma to find prognostic factors Hiroyuki Takamatsu Received Received
  P-32 Lenalidomide maintenance after autologous hematopoetic stem cell transplantation in Hungary from 2016 to 2021 Viktor Lakatos Received Received
  P-42 Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma Andrew Yee Received Received
  P-43 Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias using DW-MRI and Exploratory Bone Biomarkers Gaurav Agarwal Received Received
  P-46 Maintenance Therapy Cessation for Patients with Three-Year Sustained MRD Negative Remissions: Initial Results from a Phase II Study Neha Korde Received Received
  P-51 Sustained Bone Marrow and Imaging MRD negativity as indicators to discontinue lenalidomide maintenance after ASCT; preliminary results of a single-center prospective cohort study Panagiotis Malandrakis Received Received
  P-57 Studying microRNAs from Extracellular Vesicles as potential biomarkers in liquid biopsies of Multiple Myeloma patients Rui Bergantim Received Received
  P-58 Identifying microRNAs as potential biomarkers of drug resistance in Multiple Myeloma patients: proof-of-concept study Rui Bergantim Received Received
  P-62 MAF translocations are enriched in high-risk NDMM patients with elevated levels of circulating tumor cells suggesting a genetic basis for the aggressive disease course Cathelijne Fokkema Received Received
  P-64 Evaluation of single nucleotide variants of CDKN1A, TP53BP, and XRCC1 genes in multiple myeloma patients undergoing hematopoietic stem cells transplant and their association with treatment response. David Garrido Received Received
  P-65 Development of a mass cytometry-based toolkit to investigate myeloma therapeutic responses ex vivo Sarah Gooding Received Received
  P-82 Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma Madelon de Jong Received Received
  P-91 Thrombocytopenia with coagulation abnormality in multiple myeloma patients treated with proteasome inhibitor and/or immunomodulatory drugs. Kazuhito Suzuki Received Received
  P-92 Impaired glutamine/glutamate metabolic axis into myeloma microenvironment affects osteoclast formation. Nicola Giuliani Received Received
  P-104 Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma Julia Huber Received Received
  P-109 ER-phagic Control of Lipid Metabolism Supports Multiple Myeloma Cell Survival SIMONE CENCI Received Received
  P-110 Activity and tolerability of lenalidomide (LLD) is enhanced following low-dose continuous percutaneous delivery compared to once daily dosing in an NCIH929 MM Xenograft model in SCID mice Jamie Oliver Received Received
  P-111 Targeting the Mitochondrial Protease ClpP Unveils Novel Vulnerabilities in Multiple Myeloma SIMONE CENCI Received Received
  P-112 Anti-BCMA therapy in multiple myeloma. A single-center experience. Borja Puertas Martínez Received Received
  P-117 High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma Philip Weir Received Received
  P-122 Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma: A Population Based Study Samer Al Hadidi Received Received
  P-125 Multiple myeloma in Reunion Island : a descriptive and pronostic study on newly diagnosed patients between 2015 and 2019. Romain Chane-Teng Received Received
  P-140 Outreach and Satellite Transplant Clinics Increase Multiple Myeloma (MM) Transplant Referrals and Specifically Transplant Referrals of African American Patients Anand Jillella Received Received
  P-141 Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant Marcella Kaddoura Received Received
  P-143 SLIM CRAB Criteria revisited: A meta-analysis of studies on biomarker defined early multiple myeloma Heinz Ludwig Received Received
  P-145 The clinical significance of a MGUS Tumor Board Sandy Mazzoni Received Received
  P-146 Screening Technique for M-proteins in Acetonitrile Precipitates of Serum using MALDI-TOF Mass Spectrometry: A Comparison with Serum Immunofixation Electrophoresis and Serum Free Light Chain Assay Nikita Mehra Received Received
  P-148 Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents Ioannis Ntanasis-Stathopoulos Received Received
  P-149 Prevalence of type 1 Gaucher disease in patients with multiple myeloma: interim analysis of a prospective, multicentre, observational study massimo offidani Received Received
  P-150 Identification of misclassified multiple myeloma patient risk subgroups with a novel biological disease stratifier Afsaneh Panahi Received Received
  P-151 Primary Plasma cell Leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group. Camila Peña Received Received
  P-152 Prevalence of Monoclonal Gammopathies in adult Uruguayan population Lucia Pérez Baliero Received Received
  P-153 Impact of t(11;14) in multiple myeloma on response to treatment and survival. Borja Puertas Martínez Received Received
  P-156 Evaluation of SAVED and IMPEDE-VTE Scoring Systems for Venous Thromboembolism Prophylaxis in Patients with Multiple Myeloma Christopher Sandifer Received Received
  P-157 Carfilzomib (CFZ) resistance is associated with significant deregulation of the BH3 family proteins in multiple myeloma (MM) Anja Schneller Received Received
  P-158 End-of-life treatment and treatment costs of multiple myeloma patients in a real-world setting: a retrospective analysis of 91 patients from diagnosis to death Maarten Seefat Received Received
  P-161 Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a single-center, prospective study Vassiliki Spiliopoulou Received Received
  P-163 MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA: THE MYLORD STUDY FROM THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS) Oana Mihailescu Received Received
  P-178 A Pilot Plant Based Dietary Intervention in MGUS And SMM is Feasible and Associated with Reduction in Insulin and Leptin Levels Urvi Shah Received Received
  P-179 Comorbidities associated with Monoclonal Gammopathy of Undetermined Significance, Its Subtypes, and Risk Factors Lawanya Singh Received Received
  P-183 Outcomes in Respiratory Tract Infections in Hospitalized Multiple Myeloma Patients with Asthma and Chronic Obstructive Pulmonary Disease Kuldeepsinh Atodaria Received Received
  P-188 Moving from Research Priorities to Clinical Research: Implementing the Results of a Priority Setting Partnership on Multiple Myeloma Samantha Fowler Received Received
  P-190 Bone Remineralization of Lytic Lesions in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, Dexamethasone /- Daratumumab Induction Regimen Carlyn Tan Received Received
  P-191 The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review Hira Mian Received Received
  P-192 Patient Reported Outcome & Family Reported Outcome and The Most Correlated Clinical Measures Over One Year of Follow-Up Kareem Midlig Received Received
  P-197 A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. Carinae study Gonzalez-Pardo Miriam Received Received
  P-210 IMPACT OF PRE-TRANSPLANT DISEASE STATUS AND POST-TRANSPLANT MAINTENANCE THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT Vinay Edlukudige Keshava Received Received
  P-213 Efficacy and Safety of Bortezomib in Once Weekly vs. Twice Weekly Dosing in the Treatment of Multiple Myeloma Kwan-Keat Ang Received Received
  P-215 D-VTd as induction therapy in newly diagnosed multiple myeloma (NDMM) patients who are candidates for transplantation: A Real-Life Experience in a single center Carmen Martínez Chamorro Received Received
  P-218 Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and Related Diseases Registries. Justin Ng Received Received
  P-219 Daratumumab (DARA) lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN Mary Angelozzi Received Received
  P-222 A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients Raija Silvennoinen Received Received
  P-242 Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) patients with del17p and other high-risk abnormalities (A retrospective single-center study) HAMID EHSAN Received Received
  P-247 Addressing the Knowledge Gap to Optimize Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma Elizabeth Heller Received Received
  P-249 Real world evidence and outcomes of patients who are exposed or refractory to lenalidomide at the time of first relapse: a Greek registry analysis Sachin Patel Received Received
  P-255 Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context: Interim Analysis of the Retrospective IMAGE Study Mackenzie Baciuska Received Received
  P-258 Real-world Experience With Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis Mackenzie Baciuska Received Received
  P-260 Daratumumab (DARA) Plus Bortezomib and Dexamethasone (D-Vd) or Lenalidomide and Dexamethasone (D-Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analyses of CASTOR and POLLUX Nicole Triolo Received Received
  P-266 Favorable Outcomes of 3-weekly Daratumumab-based Regimens in Relapsed/Refractory Multiple Myeloma: Impact of MRD, Rapid Doubling Time, LDH, Triplets and Quadruplets Cheong Ngai Received Received
  P-267 Subcutaneous Isatuximab Administration by An On-Body Delivery System in Combination with Pomalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Interim Phase 1b Study Results Vasudha Chachra Received Received
  P-270 GO41036: A Phase Ia/Ib open-label, multicenter study evaluating the safety and pharmacokinetics of tiragolumab in combination with atezolizumab and daratumumab in patients with R/R MM James Bailey Received Received
  P-277 Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma Remi TILMONT Received Received
  P-283 TRIATLON - TRIple CLAss exposed/refractory MultipLe MyelOma PatieNts: A real world analysis (RWA) from the Austrian Myeloma Registry (AMR) Wolfgang Willenbacher Received Received
  P-284 Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) MUKUL RASTOGI Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
22:21
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

19th International Myeloma Society Annual Meeting

 

25-27 August, Los Angeles
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 25/08/2022 TO 27/08/2022
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert